New injection aims to tame chronic hepatitis b
NCT ID NCT07617194
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new injectable drug called AHB-171 in 144 adults with chronic hepatitis B. The main goals are to check the drug's safety and how the body processes it. Some participants will also take standard oral antivirals. The study is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AHB-171 (an investigational drug given by injection)
What this could lead to
If this early study shows AHB-171 is safe and reduces hepatitis B virus levels, it could point toward a new treatment option for chronic hepatitis B.
What could go wrong
This is a very early Phase 1 trial with only 144 participants. The main goal is safety, not effectiveness. Many drugs fail at this stage, so it is too soon to know if AHB-171 will work.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
New Zealand Clinical Research
Grafton, Auckland, 1010, New Zealand
-
Queen Mary Hospital
Hong Kong, Hong Kong